Skip to content

Lantern Pharma Inc.: 10-Q filed 2025-08-13

What Lantern Pharma Inc. reported in its quarterly report filed 2025-08-13 (fiscal Q2 2025): 32 published measures, 93 facts as tagged in accession 0001641172-25-023471.

This filing

Form
10-Q (quarterly report)
Filed
2025-08-13
Fiscal period
fiscal Q2 2025
Accession
0001641172-25-023471 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Lantern Pharma Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-06-3017,420,292USD
At 2024-12-3125,571,792USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-06-304,897,887USD
At 2024-12-314,384,018USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-06-3012,522,405USD
At 2025-03-3116,776,485USD
At 2024-12-3121,187,774USD
At 2024-06-3030,931,437USD
At 2024-03-3135,765,217USD
At 2023-12-3140,907,934USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-06-306,061,408USD
At 2024-12-317,511,079USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-4,331,015USD91
2025-01-01 to 2025-06-30-8,867,798USD181
2025-01-01 to 2025-03-31-4,536,783USD90
2024-04-01 to 2024-06-30-4,959,506USD91
2024-01-01 to 2024-06-30-10,400,316USD182
2024-01-01 to 2024-03-31-5,440,810USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-8,312,887USD181
2024-01-01 to 2024-06-30-8,259,161USD182

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2025-01-01 to 2025-06-301,159USD181
2024-01-01 to 2024-06-306,484USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-06-3054,716USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-06-306,832,489USD181
2024-01-01 to 2024-06-30-758,231USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-06-30-84,893,415USD
At 2024-12-31-76,025,617USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-04-01 to 2025-06-3010,784,725shares91
2025-01-01 to 2025-06-3010,784,725shares181
2024-04-01 to 2024-06-3010,758,805shares91
2024-01-01 to 2024-06-3010,750,801shares182

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-04-01 to 2025-06-3010,784,725shares91
2025-01-01 to 2025-06-3010,784,725shares181
2024-04-01 to 2024-06-3010,758,805shares91
2024-01-01 to 2024-06-3010,750,801shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.4USD/shares91
2025-01-01 to 2025-06-30-0.82USD/shares181
2024-04-01 to 2024-06-30-0.46USD/shares91
2024-01-01 to 2024-06-30-0.97USD/shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.4USD/shares91
2025-01-01 to 2025-06-30-0.82USD/shares181
2024-04-01 to 2024-06-30-0.46USD/shares91
2024-01-01 to 2024-06-30-0.97USD/shares182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-06-3039,524USD
At 2024-12-3147,440USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-04-01 to 2025-06-30160,626USD91
2025-01-01 to 2025-06-30308,376USD181
2024-04-01 to 2024-06-30134,171USD91
2024-01-01 to 2024-06-30268,228USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-4,651,900USD91
2025-01-01 to 2025-06-30-9,425,932USD181
2024-04-01 to 2024-06-30-5,408,461USD91
2024-01-01 to 2024-06-30-11,140,462USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-06-3017,200,790USD
At 2024-12-3125,247,629USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-06-304,884,363USD
At 2024-12-314,331,175USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-04-01 to 2025-06-304,651,900USD91
2025-01-01 to 2025-06-309,425,932USD181
2024-04-01 to 2024-06-305,408,461USD91
2024-01-01 to 2024-06-3011,140,462USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-04-01 to 2025-06-303,068,379USD91
2025-01-01 to 2025-06-306,332,334USD181
2024-04-01 to 2024-06-303,888,737USD91
2024-01-01 to 2024-06-308,139,523USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-06-3010,784,725shares
At 2024-12-3110,784,725shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-06-3097,366,699USD
At 2024-12-3197,058,323USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2025-06-3048,043USD
At 2024-12-31153,990USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-06-30143,240USD
At 2024-12-31239,985USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-06-30145,039USD
At 2024-12-31243,657USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-06-3036,738USD
At 2024-12-3136,738USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-06-301,299,016USD
At 2024-12-311,234,566USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-4,414,706USD91
2025-01-01 to 2025-06-30-8,973,745USD181
2024-04-01 to 2024-06-30-4,967,951USD91
2024-01-01 to 2024-06-30-10,299,441USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-301,583,521USD91
2025-01-01 to 2025-06-303,093,598USD181
2024-04-01 to 2024-06-301,519,724USD91
2024-01-01 to 2024-06-303,000,939USD182

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2025-04-01 to 2025-06-30206,140USD91
2025-01-01 to 2025-06-30293,599USD181
2024-04-01 to 2024-06-30260,295USD91
2024-01-01 to 2024-06-30350,536USD182

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2025-01-01 to 2025-06-30108,000USD181
2024-01-01 to 2024-06-3091,000USD182

Inspect the source

Entity
Lantern Pharma Inc. / CIK 0001763950
Captured
2026-09-21T17:26:28.194Z
SEC response SHA-256
de4123361405efcd0291343ed94db7c24d43e6c36dbcd4d45ba588f463c7f9d1

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001763950.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))